DCVax failed the original endpoint PFS.. The placebo group did better. Then they spoiled any potential comparisons with crossover. Furthermore, the only OS benefits produced were with external controls where patients did not have the same level of disease progression, methylated vs un-methylated, surgical,... etc. Why do you think they changed everything and it's been 7 years since the trial ended without an approval from a single RA?
I said IBRX's method was promising. FDA approved it for bladder, and Saudi Arabia just approved it for Lung Cancer... I don't own that stock either, but would consider buying it on a significant pull back. $3-$4 perhaps and depending on developing progress with FDA.
Market Data 
Markets 
AI
